SK Telecom Co. Ltd. Common Stock vs TG Therapeutics Inc — how do they compare? SK Telecom Co. Ltd. Common Stock trades at $34.24 (market cap $13.36B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: SK Telecom Co. Ltd. Common Stock is the larger of the two by market cap, and SK Telecom Co. Ltd. Common Stock pays a 2.85% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold SK Telecom Co. Ltd. Common Stock for 1 Days and TG Therapeutics Inc for 16 Days on average.
| SKM | TGTX | |
|---|---|---|
Market Cap | $13.36B | $8.16B |
Volume | 1,302,042 | 1,735,121 |
Sector | Media | Health |
52-Week High | $46.00 | $59.06 |
52-Week Low | $19.68 | $26.94 |
Typical Hold Time | 1 Days | 16 Days |
Enterprise Value | $19.41B | $8.37B |
Dividend Yield | 2.85% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
SK Telecom is a South Korean telecommunications company providing mobile, broadband, and digital services. It also develops services in areas such as AI, cloud, and data centers.
Read more on SKM →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →